metastatic castration-resistant prostate cancer
FDA Expands Pluvicto’s Metastatic Castration-Resistant Prostate Cancer Indication
The FDA expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults ...
APRIL 2, 2025
Early Survival Benefit Validates Addition of Radium-244 to Metastatic Prostate Cancer
In men with metastatic castration-resistant prostate cancer (mCRPC), the addition of Radium-233 (Ra233) (Xofigo, ...
OCTOBER 30, 2024
Akeega Plus Prednisone Approved for BRCA-mutated mCRPC
The FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), ...
AUGUST 14, 2023
Talzenna with Enzalutamide Approved for HRR Gene-mutated mCRPC
The FDA approved talazoparib (Talzenna, Pfizer) with enzalutamide for homologous recombination repair (HRR) ...
JUNE 26, 2023
Lynparza With Abiraterone and Prednisone (or Prednisolone) Approved for BRCA-mutated mCRPC
The FDA approved olaparib (Lynparza, AstraZeneca) with abiraterone and prednisone (or prednisolone) for adult ...
JUNE 2, 2023